CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04623541
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:58.678774+00:00
- Published At
- 2026-04-13T00:00:00+00:00
- Record Updated At
- 2026-04-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Relapsed/Refractory Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Richter\u0027s Syndrome", "Treatment-na\u00efve High Risk Chronic Lymphocytic Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"- protocolSection.identificationModule.nctId
"NCT04623541"- protocolSection.identificationModule.officialTitle
"A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody\u00ae-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter\u0027s Syndrome"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.